Vicriviroc/MK-2048

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVicriviroc/MK-2048
Drug Alias NameMK-2048 and VicrivirocMK-2048/VicrivirocVicriviroc and MK-2048VCV/MK-2048MK-2048A IVR +[7] 
ClassificationSmall molecules
Mechanisms of ActionHIV integrase inhibitorsVirus internalization inhibitorsC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5HIV integrase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes VicrivirocMK-2048
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Merck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme CorpNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A